BioLargo FY26 Q2 net loss widens to $4 million; revenue drops 55% to $1.25 million

Reuters2026/08/14 20:33

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

BioLargo posted a net loss of $4 million for the quarter ended June 30, 2026, widening from $1.88 million a year earlier.
Revenue fell 55% to $1.25 million, reflecting the August 2025 halt in private-label pet odor product sales tied to Pooph.
SG&A rose 23% to $3.32 million, while R&D more than doubled to $1.09 million.
ONM revenue dropped 77%, swinging to an operating loss of $110,000; BLEST third-party service revenue rose 1% to $777,000.
Liquidity: $2.19 million cash at June 30, 2026; $1.27 million working-capital deficit, with going-concern doubt without added funding.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioLargo Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-028023), on August 14, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

BioLargo FY26 Q2 net loss widens to $4 million; revenue drops 55% to $1.25 million

You may also like

Crypto prices